The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.
The U.S. Food and Drug Administration FDA has proposed a ban on bulk compounding of semaglutide and tirzepatide.
The proposal from the FDA targets bulk compounding of semaglutide. It also covers bulk compounding of tirzepatide. These two drugs face restrictions under the suggested ban.
The FDA seeks to prohibit such compounding practices for semaglutide and tirzepatide. This applies to bulk production methods involving these medications. The proposal specifies these drugs in its scope.
Semaglutide stands out as one drug in the FDA's proposal. Tirzepatide appears alongside it as the second drug targeted. Both receive mention in the ban on bulk compounding.
The proposal lists semaglutide and tirzepatide explicitly. Bulk compounding for each drug would end if the proposal passes. The FDA centers its action on these names.
Bulk compounding of semaglutide forms part of the proposal's target. The same holds for bulk compounding of tirzepatide. The FDA proposal addresses these activities directly.
This regulatory step involves semaglutide and tirzepatide compounding in bulk. The ban would apply to both drugs equally. The FDA has made this the core of its announcement.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg /product/semaglutide-10mg | ≥98% | 10mg | $49.00 |
| Tirzepatide 10mg /product/tirzepatide-10mg | ≥98% | 10mg | $34.00 |
Browse Full Catalog → /catalog
Peptides referenced: Semaglutide, Tirzepatide.
Related reading: FDA Moves to Restrict Bulk Compounding of Novo, Lilly Weight-Loss Drugs, GLP-1 Agonists Linked to Better Breast Cancer Survival Signals, Oral Semaglutide Delivers 21.6% Weight Loss in Early Responders, 77.3% Mobility Gains, FDA Proposes Excluding GLP-1s from 503B Bulk List.